    Katharine Spink | Asterias Biotherapeutics Inc | ZoomInfo.com










 




Katharine Spink, Asterias Biotherapeutics Inc: Profile & Biography - Bloomberg


































































  























Feedback





Katharine Spink

Exec VP/COO,
Asterias Biotherapeutics Inc






Career History




Exec VP/COO
Asterias Biotherapeutics Inc, 6/2017-PRESENT


VP/COO
Asterias Biotherapeutics Inc, 3/2013-6/2017


VP:Operations
Geron Corp, 2009-2011


Senior Dir:Cell Therepies
Geron Corp, 2008-2009


Program Director
Geron Corp, 1/2007-1/2008


Various Positions
Geron Corp, 2003-2006


Senior VP:Alliance Mgmt
Geron Corp, 2011-UNKNOWN


Show More









Website:
www.asteriasbiotherapeutics.com






Corporate Information
Address:

6300 Dumbarton Circle
Fremont, CA 94555
United States


Phone:
1-510-456-3800


Fax:
1-510-456-3796


Web url:
www.asteriasbiotherapeutics.com











From The Web












Personal Information



Education



William Marsh Rice University
Bachelor's Degree, Biochemistry


Stanford University
PhD








Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data

































Katharine E. Spink Ph.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 5:03 PM ET
Biotechnology

Company Overview of Asterias Biotherapeutics, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Katharine E. Spink Ph.D.Executive VP and Chief Operating Officer, Asterias Biotherapeutics, Inc.AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 2 different industries.43$879,027As of Fiscal Year 2016
Background

		Dr. Katharine E. Spink, also known as Katy, Ph.D., has been the Chief Operating Officer and Executive Vice President of Asterias Biotherapeutics, Inc. since March 2013 and June 26, 2017 respectively. Dr. Spink served as Vice President of Asterias Biotherapeutics, Inc. until September 05, 2015. Dr. Spink served as Senior Vice President of Alliance Management and Cell Therapy Product Development at Geron Corporation until November 2011. She served as a Senior Vice President ... of Operations for Cell Therapy Programs at Geron Corporation since February 2011. Dr. Spink served as a Vice President of Operations for Regenerative Medicine Programs at Geron Corporation from February 2009 to February 2011. From January 2008 to February 2009, Dr. Spink served as a Senior Director of Regenerative Medicine Program Operations at Geron Corporation. From January 2007 to January 2008, Dr. Spink served as Program Director of Cardiovascular Disease at Geron Corporation. Dr. Spink joined Geron in December 2003 and served various roles within Corporate Development group until January 2007. Prior to joining Geron, Dr. Spink was a management consultant at McKinsey & Company, advising clients in the biotechnology, pharmaceutical and medical device industries on matters relating to R&D strategy, business development and marketing. Dr. Spink graduated Magna Cum Laude and Phi Beta Kappa with a B.A. in Biochemistry from Rice University and received her Ph.D. in Cancer Biology from Stanford University.Read Full Background




Corporate Headquarters
6300 Dumbarton CircleFremont, California 94555United StatesPhone: 510-456-3800Fax: 510-456-3796
Board Members Memberships
				There is no Board Members Memberships data available.
				Education
PhD Stanford UniversityBA Rice University
Other Affiliations
Geron CorporationStanford UniversityRice University


Annual Compensation
Salary$314,100Total Annual Compensation$314,100
Stocks Options
Restricted Stock Awards$155,224All Other Compensation$13,027Exercisable Options$240,415Exercisable Options Value$401,215Unexercisable Options$309,585Unexercisable Options Value$245,285Total Value of Options$646,500Total Number of Options$550,000
Total Compensation
Total Annual Cash Compensation$327,127Total Short Term Compensation$314,100Other Long Term Compensation$168,251Total Calculated Compensation$879,027




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Asterias Biotherapeutics, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























AST Katharine E. Spink Insider Trades for Asterias Biotherapeutics Inc.


































Bulletin

Trump tweets he has named John Kelly new chief of staff »
        




Investor Alert







New York Markets After Hours



Market Snapshot
Winners and Losers


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Asterias Biotherapeutics Inc.

                  NYSE American: AST
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Asterias Biotherapeutics Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 28, 2017, 4:30 p.m.


AST

/quotes/zigman/39963244/composite


$
3.50




Change

0.00
0.00%

Volume
Volume 1,488
Quotes are delayed by 20 min








/quotes/zigman/39963244/composite
Today's close

$
			3.55
		


$
				3.50
			
Change

-0.05
-1.41%





Day low
Day high
$3.50
$3.63










52 week low
52 week high

            $2.54
        

            $5.80
        


















Insider Activity


Individual




Katharine E. Spink



Dr. Katharine E. Spink is Chief Operating Officer & Vice President at Asterias Biotherapeutics, Inc.
Dr. Spink was previously employed as Senior VP-Alliance Management & Operations by Geron Corp.
She received her undergraduate degree from Rice University and a doctorate degree from the Stanford University School of Medicine.



Transactions


Date
Shares
Transaction
Value





06/05/2017
7,260


 
Derivative/Non-derivative trans. at $3.2 per share.


23,232


03/30/2017
18,209


 
Award at $0 per share.


0


01/09/2017
4,781


 
Disposition at $4.6 per share.


21,993


01/09/2017
2,878


 
Derivative/Non-derivative trans. at $0 per share.


0


12/27/2016
2,500


 
Disposition at $5 per share.


12,500


12/27/2016
2,500


 
Derivative/Non-derivative trans. at $2.34 per share.


5,850


11/23/2016
2,500


 
Disposition at $5.41 per share.


13,525


11/23/2016
2,500


 
Derivative/Non-derivative trans. at $2.34 per share.


5,850


11/17/2016
2,500


 
Disposition at $5 per share.


12,500


11/17/2016
2,500


 
Derivative/Non-derivative trans. at $2.34 per share.


5,850


10/06/2016
4,781


 
Disposition at $4.11 per share.


19,650


10/06/2016
2,878


 
Derivative/Non-derivative trans. at $0 per share.


0


09/09/2016
9,608


 
Disposition at $3.54 per share.


34,013


09/08/2016
9,728


 
Disposition at $3.5 per share.


34,048


03/25/2016
30,635


 
Award at $0 per share.


0


09/15/2015
3,760


 
Disposition at $6 per share.


22,560


06/30/2015
3,291


 
Derivative/Non-derivative trans. at $4.6 per share.


15,139





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Michael H. Mulroy 
President & Chief Executive Officer




Dr. Katharine E. Spink 
Chief Operating Officer & Vice President




Mr. Ryan D. Chavez 
CFO, Secretary & General Counsel




Dr. Jane S. Lebkowski 
Chief Scientific Officer




Dr. Edward D. Wirth 
Chief Medical Officer




Mr. Aditya P. Mohanty 
Director




Dr. Michael D. West 
Director




Mr. Alfred Dennis Kingsley 
Director




Mr. Frank  Lanza 
Vice President & Controller




Mr. Don Matthew Bailey 
Non-Executive Chairman




Dr. Howard I. Scher 
Independent Director




Mr. Andrew  Arno 
Independent Director




Mr. Natale S. Ricciardi 
Independent Director




Mr. Richard Towne LeBuhn 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




5:03 PM EDT
July 28, 2017


/marketstate/country/us
New York

	After


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
5:00pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
4:56pBREAKINGIn a tweet, Trump names Gen. Kelly his new chief of staff
4:56pMattel could get wrecked by weak ‘Cars 3’ toy sales
4:55pThis 1 number sums up why that Foxconn deal is over-the-top bad for Wisconsin
4:51pBREAKINGTrump tweets he's named a new chief of staff, John Kelly
4:42pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
4:34pLong-dated Treasury yields see weekly climb 
4:33pS&P 500, Nasdaq finish lower after Amazon disappointment; Dow closes at record
4:32pThe highest paid athletes in the world, in one chart
4:32pHow to raise your kids to be frugal (but not too frugal)
4:31pCities to move to if you want to work in tech — NOT including San Francisco
4:31pWhat Donald Trump’s battle of wills with Jeff Sessions teaches you about a difficult boss
4:31pOne way you’re paying credit-card fees, even if you don’t have a card
4:30pTrump, Russia and Sanctions: What We Know 
4:30pThis is the worst mistake people make at work
4:30pMove over, breathalyzers; ‘textalyzers’ could be used on drivers’ phones 
4:29pJared Kushner’s unorthodox approach to meetings is a cautionary tale for office workers everywhere
4:28pHere’s how much you should spend on a yoga mat 
4:26p5 weird things I found out about America in my first 24 hours 
4:26pWeekend Sip: Is this the world’s first distilled non-alcoholic spirit?
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15


























































    AST Key Statistics - Asterias Biotherapeutics Inc. Financial Ratios - MarketWatch




































Bulletin

Trump tweets he has named John Kelly new chief of staff »
        




Investor Alert







New York Markets After Hours



Market Snapshot
Winners and Losers


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Asterias Biotherapeutics Inc.

                  NYSE American: AST
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Asterias Biotherapeutics Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 28, 2017, 4:30 p.m.


AST

/quotes/zigman/39963244/composite


$
3.50




Change

0.00
0.00%

Volume
Volume 1,488
Quotes are delayed by 20 min








/quotes/zigman/39963244/composite
Today's close

$
			3.55
		


$
				3.50
			
Change

-0.05
-1.41%





Day low
Day high
$3.50
$3.63










52 week low
52 week high

            $2.54
        

            $5.80
        

















			Company Description 


			Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical ne...
		


                Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA.
            




Valuation

P/E Current
-4.40


P/E Ratio (with extraordinary items)
-5.61


Price to Sales Ratio
28.40


Price to Book Ratio
5.21


Enterprise Value to EBITDA
-4.87


Enterprise Value to Sales
18.31


Total Debt to Enterprise Value
0.00

Efficiency

Revenue/Employee
126,436.00


Income Per Employee
-645,255.00


Receivables Turnover
24.53


Total Asset Turnover
0.11

Liquidity

Current Ratio
6.11


Quick Ratio
6.11


Cash Ratio
5.80



Profitability

Gross Margin
42.62


Operating Margin
-453.88


Pretax Margin
-543.77


Net Margin
-510.34


Return on Assets
-55.46


Return on Equity
-81.46


Return on Total Capital
-81.41


Return on Invested Capital
-81.42

Capital Structure

Total Debt to Total Equity
0.06


Total Debt to Total Capital
0.06


Total Debt to Total Assets
0.04


Long-Term Debt to Equity
0.05


Long-Term Debt to Total Capital
0.05





      Officers and Executives
    



Name
Age
Officer Since
Title





Mr. Michael H. Mulroy 
51
2017
President & Chief Executive Officer



Dr. Katharine E. Spink 
42
2013
Chief Operating Officer & Vice President



Mr. Ryan D. Chavez 
41
2016
CFO, Secretary & General Counsel



Dr. Jane S. Lebkowski 
61
2013
Chief Scientific Officer



Dr. Edward D. Wirth 
50
2013
Chief Medical Officer





Insider Actions


 – Purchase

 – Sale
1
 – Number of Transactions











{"OrganizationDocuments":[{"Documents":[{"document":[{"reportDateGroup":[{"reportDate":"2011-06-09","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-05-17","tradeTypeGroup":[{"numTransactions":"3","tradeType":"D"},{"numTransactions":"1","tradeType":"A"}]},{"reportDate":"2011-05-16","tradeTypeGroup":[{"numTransactions":"2","tradeType":"D"},{"numTransactions":"8","tradeType":"A"}]},{"reportDate":"2011-05-13","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-12","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-11","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-02","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-03-10","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-02-17","tradeTypeGroup":[{"numTransactions":"4","tradeType":"D"},{"numTransactions":"2","tradeType":"A"}]},{"reportDate":"2011-02-15","tradeTypeGroup":[{"numTransactions":"8","tradeType":"A"},{"numTransactions":"1","tradeType":"D"}]}]}]}]}]}


Date
Name
Shares
Transaction
Value





06/05/2017

Jane S. Lebkowski 
Chief Scientific Officer

7,015


 
Derivative/Non-derivative trans. at $3.2 per share.


22,448


06/05/2017

Katharine E. Spink 
EVP & COO

7,260


 
Derivative/Non-derivative trans. at $3.2 per share.


23,232


06/05/2017

Edward D. Wirth 
Chief Medical Officer

6,745


 
Derivative/Non-derivative trans. at $3.2 per share.


21,584


03/30/2017

Stephen Lahue Cartt                            
Director

32,783


 
Award at $0 per share.


0


03/30/2017

Jane S. Lebkowski 
Chief Scientific Officer

75,000


 
Award at $0 per share.


0


03/30/2017

Jane S. Lebkowski 
Chief Scientific Officer

17,670


 
Award at $0 per share.


0


03/30/2017

Katharine E. Spink 
EVP & COO

18,209


 
Award at $0 per share.


0


03/30/2017

Edward D. Wirth 
Chief Medical Officer

75,000


 
Award at $0 per share.


0


03/30/2017

Edward D. Wirth 
Chief Medical Officer

16,922


 
Award at $0 per share.


0


03/30/2017

Ryan D. Chavez 
CFO and General Counsel

75,000


 
Award at $0 per share.


0


03/30/2017

Ryan D. Chavez 
CFO and General Counsel

9,565


 
Award at $0 per share.


0


01/09/2017

Jane S. Lebkowski 
Chief Scientific Officer

2,537


 
Derivative/Non-derivative trans. at $0 per share.


0


01/09/2017

Katharine E. Spink 
EVP & COO

2,878


 
Derivative/Non-derivative trans. at $0 per share.


0


01/09/2017

Edward D. Wirth 
Chief Medical Officer

2,056


 
Derivative/Non-derivative trans. at $0 per share.


0


01/09/2017

Katharine E. Spink 
EVP & COO

4,781


 
Disposition at $4.6 per share.


21,992


01/09/2017

Edward D. Wirth 
Chief Medical Officer

3,415


 
Disposition at $4.6 per share.


15,709


12/27/2016

Katharine E. Spink 
EVP & COO

2,500


 
Disposition at $5 per share.


12,500


12/27/2016

Edward D. Wirth 
Chief Medical Officer

2,500


 
Disposition at $5 per share.


12,500


12/27/2016

Katharine E. Spink 
EVP & COO

2,500


 
Derivative/Non-derivative trans. at $2.34 per share.


5,850


12/27/2016

Edward D. Wirth 
Chief Medical Officer

2,500


 
Derivative/Non-derivative trans. at $2.34 per share.


5,850


11/23/2016

Katharine E. Spink 
EVP & COO

2,500


 
Disposition at $5.41 per share.


13,525


11/23/2016

Katharine E. Spink 
EVP & COO

2,500


 
Derivative/Non-derivative trans. at $2.34 per share.


5,850


11/17/2016

Katharine E. Spink 
EVP & COO

2,500


 
Disposition at $5 per share.


12,500


11/17/2016

Edward D. Wirth 
Chief Medical Officer

2,500


 
Disposition at $5 per share.


12,500


11/17/2016

Katharine E. Spink 
EVP & COO

2,500


 
Derivative/Non-derivative trans. at $2.34 per share.


5,850


11/17/2016

Edward D. Wirth 
Chief Medical Officer

2,500


 
Derivative/Non-derivative trans. at $2.34 per share.


5,850


10/06/2016

Jane S. Lebkowski 
Chief Scientific Officer

2,537


 
Derivative/Non-derivative trans. at $0 per share.


0


10/06/2016

Katharine E. Spink 
EVP & COO

2,878


 
Derivative/Non-derivative trans. at $0 per share.


0


10/06/2016

Edward D. Wirth 
Chief Medical Officer

2,055


 
Derivative/Non-derivative trans. at $0 per share.


0


10/06/2016

Katharine E. Spink 
EVP & COO

4,781


 
Disposition at $4.11 per share.


19,649


10/06/2016

Edward D. Wirth 
Chief Medical Officer

3,415


 
Disposition at $4.12 per share.


14,069


09/09/2016

Katharine E. Spink 
EVP & COO

9,608


 
Disposition at $3.54 per share.


34,012


09/09/2016

Edward D. Wirth 
Chief Medical Officer

3,179


 
Disposition at $3.58 per share.


11,380


09/08/2016

Katharine E. Spink 
EVP & COO

9,728


 
Disposition at $3.5 per share.


34,048


09/08/2016

Edward D. Wirth 
Chief Medical Officer

11,581


 
Disposition at $3.5 per share.


40,533


06/30/2016

Stephen Lahue Cartt                            
Director

10,000


 
Acquisition at $2.4 per share.


24,000








/news/latest/company/us/ast

      MarketWatch News on AST
    
No News currently available for AST





/news/nonmarketwatch/company/us/ast

      Other News on AST
    





3 Things In Biotech You Should Learn Today: July 19, 2017

9:00 a.m. July 19, 2017
 - Seeking Alpha





Asterias Bio completes enrollment in 20M-cell cohort in spinal cord injury study

9:16 a.m. July 17, 2017
 - Seeking Alpha





Asterias completes enrollment and dosing in 10M cell cohort in SCiStar study

7:22 a.m. July 12, 2017
 - Seeking Alpha





3 Things In Biotech You Should Learn Today: June 14, 2017

11:09 a.m. June 14, 2017
 - Seeking Alpha





Spinal cord injury patients continue to improve in Asterias Bio's SCiStar study; shares ahead 8% premarket

9:14 a.m. June 13, 2017
 - Seeking Alpha





3 Things In Biotech You Should Learn Today: May 12, 2017

12:06 p.m. May 12, 2017
 - Seeking Alpha





Asterias Biotherapeutics' (AST) CEO Stephen Cartt on Q1 2017 Results - Earnings Call Transcript

11:19 p.m. May 11, 2017
 - Seeking Alpha




 10-Q: ASTERIAS BIOTHERAPEUTICS, INC.
5:08 p.m. May 11, 2017
 - Edgar Online -  (EDG = 10Q, 10K)





BioTime Inc.: Sifting Through Numerous Trials For Potential Opportunities

2:19 p.m. May 1, 2017
 - Seeking Alpha





Asterias Bio's study of AST-OPC1 in acute spinal cord injury to continue; shares ahead 10%

12:51 p.m. April 25, 2017
 - Seeking Alpha





Asterias Biotherapeutics' (AST) CEO Stephen Cartt on Q4 2016 Results - Earnings Call Transcript

8:09 p.m. March 28, 2017
 - Seeking Alpha




 10-K: ASTERIAS BIOTHERAPEUTICS, INC.
5:24 p.m. March 28, 2017
 - Edgar Online -  (EDG = 10Q, 10K)





Asterias Bio's cell therapy continues to demonstrate treatment effect in spinal cord injury patients; shares ahead 12%

10:12 a.m. March 21, 2017
 - Seeking Alpha





Biotech Forum Daily Digest: Biotech Awaits Clarity; Differing Opinions On Biogen; Spotlight On Paratek

12:35 p.m. Jan. 25, 2017
 - Seeking Alpha





Asterias Has Strong Upside Potential In 2017

9:51 a.m. Jan. 24, 2017
 - Seeking Alpha





Spinal cord injury patients continue to improve following treatment with Asterias Bio's AST-OPC1 cells; shares ahead 4% premarket

9:50 a.m. Jan. 24, 2017
 - Seeking Alpha





President Obama Signs 21st Century Cures Act - Implications For The Stem Cell Sector

8:01 a.m. Dec. 14, 2016
 - Seeking Alpha





Small Caps Biggest Winners

6:20 a.m. Nov. 29, 2016
 - Seeking Alpha





Hottest Manufacturing Stocks Now – PHMD CAAS ALBO CFRX

5:30 p.m. Nov. 25, 2016
 - InvestorPlace.com





Hottest Manufacturing Stocks Now – HTBX RGLS CAAS ACHN

6:00 p.m. Nov. 23, 2016
 - InvestorPlace.com


Loading more headlines...












At a Glance

Asterias Biotherapeutics, Inc.
6300 Dumbarton Circle


Fremont, California 94555




Phone
1 5104563800


Industry
Biotechnology


Sector
Health Care/Life Sciences


Fiscal Year-end
12/2017


View SEC Filings




Revenue
$6.95M


Net Income
$-35.49M


2016 Sales Growth 
94.1%


Employees

        55.00


Annual Report for AST











/news/pressrelease/company/us/ast

      Press Releases on AST
    




 Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-A 20 Million Cell Cohort
7:00 a.m. July 17, 2017
 - PR Newswire - PRF




 Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort
7:00 a.m. July 12, 2017
 - PR Newswire - PRF




 Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study
7:00 a.m. July 10, 2017
 - PR Newswire - PRF




 AIVITA Comments on Positive Findings from Asterias' SCiStar Trial for Spinal Cord Injury
5:17 p.m. June 13, 2017
 - PR Newswire - PRF




 Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias' AST-OPC1
8:00 a.m. June 13, 2017
 - PR Newswire - PRF




 Asterias Biotherapeutics to Present New 9-Month Efficacy Data from AST-OPC1 SCiStar Study at the International Society for Stem Cell Research (ISSCR) 2017 Annual Meeting
7:00 a.m. June 8, 2017
 - PR Newswire - PRF




 Asterias Biotherapeutics Announces Top Leadership Transition
4:10 p.m. May 23, 2017
 - PR Newswire - PRF




 Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
4:01 p.m. May 11, 2017
 - PR Newswire - PRF




 New MRI Data from Asterias' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord Injury
7:00 a.m. May 11, 2017
 - PR Newswire - PRF




 Asterias Biotherapeutics to Report First Quarter Results on May 11, 2017
7:00 a.m. May 4, 2017
 - PR Newswire - PRF




 Presidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting Will Feature Presentation on Asterias' AST-OPC1 for Spinal Cord Injury
7:00 a.m. May 3, 2017
 - PR Newswire - PRF




 Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
7:00 a.m. April 26, 2017
 - PR Newswire - PRF




 Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Cervical Spinal Cord Injury
7:00 a.m. April 25, 2017
 - PR Newswire - PRF




 Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress
4:01 p.m. March 28, 2017
 - PR Newswire - PRF




 Update on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment
7:00 a.m. March 21, 2017
 - PR Newswire - PRF




 Asterias Biotherapeutics to Report Fourth Quarter and Full Year Results on March 28, 2017
8:00 a.m. March 7, 2017
 - PR Newswire - PRF




 Asterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position
8:00 a.m. Feb. 3, 2017
 - PR Newswire - PRF




 Asterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries
8:00 a.m. Jan. 24, 2017
 - PR Newswire - PRF




 Asterias Announces Conference Call to Discuss 6-month Efficacy Data from AST-OPC1 SCiStar Study
8:30 a.m. Jan. 18, 2017
 - PR Newswire - PRF




 Asterias Announces Successful Commencement of Operations at New GMP Manufacturing Facility for AST-OPC1
8:00 a.m. Jan. 9, 2017
 - PR Newswire - PRF


Loading more headlines...









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




5:03 PM EDT
July 28, 2017


/marketstate/country/us
New York

	After


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
5:00pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
4:56pBREAKINGIn a tweet, Trump names Gen. Kelly his new chief of staff
4:56pMattel could get wrecked by weak ‘Cars 3’ toy sales
4:55pThis 1 number sums up why that Foxconn deal is over-the-top bad for Wisconsin
4:51pBREAKINGTrump tweets he's named a new chief of staff, John Kelly
4:42pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
4:34pLong-dated Treasury yields see weekly climb 
4:33pS&P 500, Nasdaq finish lower after Amazon disappointment; Dow closes at record
4:32pThe highest paid athletes in the world, in one chart
4:32pHow to raise your kids to be frugal (but not too frugal)
4:31pCities to move to if you want to work in tech — NOT including San Francisco
4:31pWhat Donald Trump’s battle of wills with Jeff Sessions teaches you about a difficult boss
4:31pOne way you’re paying credit-card fees, even if you don’t have a card
4:30pTrump, Russia and Sanctions: What We Know 
4:30pThis is the worst mistake people make at work
4:30pMove over, breathalyzers; ‘textalyzers’ could be used on drivers’ phones 
4:29pJared Kushner’s unorthodox approach to meetings is a cautionary tale for office workers everywhere
4:28pHere’s how much you should spend on a yoga mat 
4:26p5 weird things I found out about America in my first 24 hours 
4:26pWeekend Sip: Is this the world’s first distilled non-alcoholic spirit?
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15
































































Katharine E. Spink Ph.D. - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In




















Katharine E. Spink Ph.D.
Executive Vice President and Chief Operating Officer at Asterias Biotherapeutics, Inc.


View Full Profile
Are you Katharine E. Spink Ph.D.? Claim your profile


 


Sign up for Equilar Atlas and view Katharine E. Spink Ph.D.'s full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Katharine E. Spink Ph.D.'s  network and community.
												FOLLOW changes in Katharine E. Spink Ph.D.'s employment and money-in-motion.
												CONNECT with Katharine E. Spink Ph.D. through your network of contacts.
												








Katharine E. Spink Ph.D.'s Executive Work History


Current


Executive Vice President and Chief Operating Officer, 
Asterias Biotherapeutics, Inc.


Past
To view Katharine E. Spink Ph.D.'s complete executive work history, sign up now
Age
42

 
 


Katharine E. Spink Ph.D.'s Biography



Katharine E. Spink, Ph.D., 42, became our Chief Operating Officer during March 2013. Prior to her serving as our Vice President and Chief Operating Officer, she served as an independent consultant at Spink Consulting, after an eight year career at Geron where she served as Senior Vice President of Alliance Management and Cell Therapy Product Development, and of Operations, Cell Therapies during 2011; Vice President of Operations, Regenerative Medicine Programs from 2009 to 2011; and Senior Director of Program Operations, Regenerative Medicine from 2008 to 2009. From January 2007 until January 2008, Dr. Spink served as Program Director for Car ...
(Read More)

			Katharine E. Spink, Ph.D., 42, became our Chief Operating Officer during March 2013. Prior to her serving as our Vice President and Chief Operating Officer, she served as an independent consultant at Spink Consulting, after an eight year career at Geron where she served as Senior Vice President of Alliance Management and Cell Therapy Product Development, and of Operations, Cell Therapies during 2011; Vice President of Operations, Regenerative Medicine Programs from 2009 to 2011; and Senior Director of Program Operations, Regenerative Medicine from 2008 to 2009. From January 2007 until January 2008, Dr. Spink served as Program Director for Cardiovascular Disease, and was Assistant Director, and then Associate Director of Corporate Development during 2003 to 2006. Dr. Spink holds a B.A. in Biochemistry from Rice University, and a Ph.D. in Cancer Biology from Stanford University School of Medicine.
		
Source: Asterias Biotherapeutics, Inc. on 05/01/2017
		
	

 






Sign up for Equilar Atlas and view Katharine E. Spink Ph.D.'s full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Katharine E. Spink Ph.D.. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Katharine E. Spink Ph.D.'s  network and community.
												FOLLOW changes in Katharine E. Spink Ph.D.'s employment and money-in-motion.
												CONNECT with Katharine E. Spink Ph.D. through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Katharine E. Spink Ph.D.


















Katharine E. Spink Ph.D.'s Connections (36)





Sign up now to view Katharine E. Spink Ph.D.'s 36 connections »









Robert W. Peabody
Former Chief Financial Officer, LifeMap Solutions Inc., BioTime, Inc.









Michael D. West
Dir. and Co-Chief Executive Officer, BioTime, Inc.









Judith Segall
Former VICE PRESIDENT OF ADMINISTRATION, CORPORATE SECRETARY, BioTime, Inc.









David J. Earp
Former Senior Vice President, Corporate Transactions, Geron Corporation









Edward V. Fritzky
Former Board Member, Jacobs Engineering Group Inc.









Pedro Lichtinger
Board Member, Gemphire Therapeutics









Thomas B. Okarma
Former President and Chief Executive Officer, Asterias Biotherapeutics, Inc.









Andrew Arno
Board Member, Smith Micro Software, Inc.









Natale S. Ricciardi
Board Member, Dynavax Technologies Corporation









Robert J. Spiegel
Board Member, Geron Corporation








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Carl G. Annessa
EVP and COO, Hornbeck Offshore Services, Inc.









Elon R. Musk
CEO and Chairman, Tesla









Michael C. Montgomery
Board Member, NMI Holdings, Inc.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

ï¿½ 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993




















Asterias Biotherapeutics Inc (AST) COO Spink Katharine E.'s Insider Stock Buys and Sells 



























Home




 Homepage


 Membership Levels


 Membership Data Coverage


 Complete Stock List


 Founder's Message


 The Book


 FREE Trial






Screeners


Value Screens 


 All-In-One Screener


 Industry Overview


 Ben Graham Net-Net


 Undervalued Predictable


 Buffett-Munger Screener


 Magic Formula (Greenblatt)


 Historical Low P/S List


 Historical Low P/B List


 Peter Lynch Screen


 High Short Interest


 52-Week/3Y/5Y Lows


 52-Week/3Y/5Y Highs


 Predictable Companies


 S&P 500 Grid


 Dividend Stocks


 Spin Off List




Downloads | Tools


  Excel Add-In GURUF


 Manual of Stocks™


 Download Financial Data


 Download Guru Portfolios


 Download Stock PDFs


 Download Insider Data


  API


 Mobile App




Strategies


 Performances


 Buffett-Munger


 Undervalued Predictable


 Low P/S


 Low P/B


 Broadest Owned


 Most Weighted






Gurus




 Latest Guru Picks


 Real Time Picks


 List of Gurus (Personalize)


 Gurus Portfolios


 Scoreboard


 Top 10 Holdings View


 Sector Picks


 International Picks


 Aggregated Portfolio


 Consensus Picks


 Guru Bargains


 Hot Picks


 Industry Trends


 Geographic Trend


 ETFs


 Options


 European Shorting






Insiders




 All Insiders


 CEO Buys/Sales


 CFO Buys/Sales


 Insider Cluster


 Guru+Insider Double Buys


 Triple Buys/Sales


 Insider Trends


 Canadian Insider


 Dutch Insider






Market


Market Valuation


 Economic Data


 Industry Overview


 Market-Cap/GDP Valuation


 Global Market Valuation


 Shiller P/E


 Shiller P/E By Sectors


 Buffett Assets Allocation




By Country


 USA


 Australia


 Canada


 China


 Germany


 India


 Japan


 UK


 More...






Articles


Articles


 Editor's Picks


 GuruFocus Research


 Value Ideas


 Interviews with Gurus


 Top Ranked


 Value Idea Contest


 Videos


 Following Authors




Submit Articles


 Writers Wanted


 Value Contest Winners


 Submit Articles Online


 My Articles






Conference




 Value Conference


 Speakers


 Location/Venue


 Register


 After Conference Gathering (Free Drinks)






Tutorials




 Tutorials & Webinars


 FAQ


 Contact Us






Log In




 Free Sign-up


 Log In


 7-Day Free Trial 






Subscribe




 Free Trial ($399/Year)


 Refer a Friend & Earn $50














Search
Compare

Search ▾










Get 7-Day Free Trial



My Portfolios▾

Portfolios Overview
Create New Portfolio
Portfolio Contest


My Gurus▾

Quick Browse
Personalize

My Gurus

Premium Gurus 
Premium Plus Investors 





















SummaryCanadian Dutch CEO Buys CFO Buys Insider Cluster Buys Double Buys Triple Buys Data Export Trend  




Saved!




USA

Canada

UK/Ireland

Europe

Asia

Oceania

Latin America

Africa



Currently Selected:



Show All Countries ▾





Purchase to select this region

Purchase $399
USA

OTCPK
NAS
NYSE
ARCA
OTCBB
AMEX
BATS




Purchase to select this region

Purchase $289
Canada

TSXV
TSX
XCNQ




Purchase to select this region

Purchase $269
UK/Ireland

UK




Purchase to select this region

Purchase $399
Europe

Germany
France
Poland
Russia
Sweden
Turkey
Bosnia and Herzegovina
Italy
Luxembourg
Switzerland


Belgium
Greece
Norway
Spain
Denmark
Bulgaria
Netherlands
Romania
Finland
Serbia
Austria
Croatia
Portugal
Slovakia
Cyprus
Macedonia
Slovenia
Ukraine
Hungary
Lithuania
Latvia
Malta
Iceland
Estonia
Czech Republic

All Countries ▾



Purchase to select this region

Purchase $399
Asia

India
Japan
Korea
Thailand
Hongkong
China
Taiwan
Malaysia
Singapore
Israel


Indonesia
Pakistan
Vietnam
Philippines
Sri Lanka
Kuwait
Nepal
Saudi
Jordan
Oman
Iran
Iraq
United Arab Emirates
Kazakhstan
Bahrain

All Countries ▾



Purchase to select this region

Purchase $269
Oceania

Australia
New zealand




Purchase to select this region

Purchase $299
Latin America

Brazil
Mexico
Argentina
Chile
Peru
Columbia
Jamaica
Venezuela
Ecuador




Purchase to select this region

Purchase $249
Africa

South Africa
Egypt
Nigeria
Mauritius
Morocco
Zimbabwe
Kenya
Tunisia
Ghana
Côte d'Ivoire




 Set As Default







Insider Trades


Try Insider Screener



Asterias Biotherapeutics Inc (AST) COO Spink Katharine E.'s Insider Stock Buys and SellsTo find out why GuruFocus thinks data on insider trades is interesting, read

Can Aggregated Insider Trading Activities Predict the Market?
Stocks That Both Gurus and Insiders Are Buying
Can Aggregated Insider Trading Activities Predict the Market of Different Sectors?




Filter by:



  Default





Search Insider Trade:




Go




Select to drill down:


All Market CapMicro Cap Small Cap Mid Cap Large Cap Mega Cap S&P 500 Companies All SectorsBasic Materials Consumer Cyclical Financial Services Real Estate Consumer Defensive Healthcare Utilities Communication Services Energy Industrials Technology   Display Those with At Least
100 500 1,000 2,000 5,000 10,000 20,000 50,000 100,000  Shares Display Stocks That are within Please Select 1% 
2% 
3% 
4% 
5% 
8% 
10% 
 of Please Select 52-Week Low3-Year Low5-Year LowReal time insider type:BuySellInsider Sentiment Chart 


 Recent Filings Activity
 

Total Records: 1053664   Page:1  2   3   4   5   6   7   8   9   10   LAST (35123) 30 per page ▾ 10 20 2530 50 100



Symbol
Company
Insider
Position
Date
Buy/Sell
Shares
Trade Price ($)
Cost ($1000)
Price ChangeSince Trade (%)
Yield (%)
P/E
Market Cap ($M)
Details

ASTAsterias Biothe...Spink Katharine E.COO2017-01-09Sell4,781$4.621.99-23.91
0.000.00172.410 Link

ASTAsterias Biothe...Spink Katharine E.COO2016-12-27Sell2,500$512.5-30
0.000.00172.410 Link

ASTAsterias Biothe...Spink Katharine E.COO2016-11-23Sell2,500$5.4113.53-35.3
0.000.00172.410 Link

ASTAsterias Biothe...Spink Katharine E.COO2016-11-17Sell2,500$512.5-30
0.000.00172.410 Link

ASTAsterias Biothe...Spink Katharine E.COO2016-10-06Sell4,781$4.1119.65-14.84
0.000.00172.410 Link

ASTAsterias Biothe...Spink Katharine E.COO2016-09-09Sell19,336$3.5268.06-0.57
0.000.00172.410 Link

ASTAsterias Biothe...Spink Katharine E.VP and COO2015-09-15Sell3,760$622.56-41.67
0.000.00172.410 Link
Total Records: 1053664   Page:1  2   3   4   5   6   7   8   9   10   LAST (35123) 30 per page ▾ 10 20 2530 50 100Add this list into my watchlist/portfolio:

1. Add or remove tickers (Comma separated, up to 500 symbols)
AST





2. Select destination portfolioYou need to log in to proceed
3. Click the button to finish
 


Related News and Stories: A: Note of A 04-07-2017A: Note of A 04-07-2017A: Note of A 04-07-2017A: comment on A 01-17-2017A: comment on A 12-20-2016A: Agilent Technologies Raises Dividend 15% 12-06-2016A: Note of A 09-13-2016A: Note of A 09-09-2016A: Note of A 08-02-2016A: comment on A 11-18-2015A: comment on A 11-12-2015A: comment on A 11-08-2015A: Why Agilent Technologies is a "Hold" 06-17-2015A: comment on A 12-22-2014A: stocknote 08-21-2014 Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company. 


 



Select portfolio(s):








                        Create a new portfolio



Why you are interested?



            Your selection and notes will be stored in your portfolio.
        


Login to add portfolio















Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
                    | Earn affiliate commissions by embedding GuruFocus Charts

                                                GuruFocus Affiliate Program: Earn up to $400 per referral.  ( Learn More) 













Home  About   Jobs    Advertise    Site Map    Term of Use    Privacy Policy     RSS    Mobile App     Email Alerts    Referral Program    Affiliate Program    FAQ    Contact Us
                               

                © 2004-2017                GuruFocus.com, LLC. All Rights Reserved.
            


                    Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC.



                    Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.


















GF Chat {{numOfNotice}}




























×
Manage BookMarks





Close








FEEDBACK














